Zacks Research Brokers Cut Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPRFree Report) – Equities researchers at Zacks Research dropped their Q1 2024 earnings estimates for Esperion Therapeutics in a note issued to investors on Tuesday, March 19th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will earn ($0.38) per share for the quarter, down from their previous estimate of ($0.36). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.80) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q2 2024 earnings at ($0.25) EPS, Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.93) EPS, Q1 2025 earnings at ($0.14) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.17 EPS and FY2025 earnings at $0.07 EPS.

Other research analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and set a $8.00 target price on shares of Esperion Therapeutics in a report on Tuesday, February 27th. Bank of America cut shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 3rd. Finally, HC Wainwright lowered their price target on shares of Esperion Therapeutics from $22.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, February 28th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $9.33.

View Our Latest Stock Report on Esperion Therapeutics

Esperion Therapeutics Trading Up 8.5 %

NASDAQ ESPR opened at $2.29 on Thursday. The company’s 50-day moving average price is $2.38 and its 200-day moving average price is $1.77. The stock has a market cap of $423.76 million, a PE ratio of -1.08 and a beta of 0.82. Esperion Therapeutics has a 12 month low of $0.70 and a 12 month high of $3.34.

Esperion Therapeutics (NASDAQ:ESPRGet Free Report) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same quarter in the previous year, the company posted ($0.76) earnings per share.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ESPR. Amalgamated Bank raised its holdings in shares of Esperion Therapeutics by 18.6% during the 4th quarter. Amalgamated Bank now owns 12,490 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 1,960 shares during the period. FMR LLC increased its stake in Esperion Therapeutics by 30.0% during the second quarter. FMR LLC now owns 8,669 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 2,003 shares during the period. UBS Group AG increased its stake in Esperion Therapeutics by 18.9% during the second quarter. UBS Group AG now owns 16,454 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 2,610 shares during the period. Citigroup Inc. increased its stake in Esperion Therapeutics by 20.1% during the fourth quarter. Citigroup Inc. now owns 15,671 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 2,619 shares during the period. Finally, American International Group Inc. increased its stake in Esperion Therapeutics by 10.3% during the fourth quarter. American International Group Inc. now owns 34,887 shares of the biopharmaceutical company’s stock worth $217,000 after purchasing an additional 3,263 shares during the period. Institutional investors and hedge funds own 69.76% of the company’s stock.

Esperion Therapeutics Company Profile

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Featured Stories

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.